Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
Open Access
- 1 March 2022
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 68 (3) , 405-412
Abstract
OBJECTIVE: In multicentric/multifocal breast tumors, there may be immunological and histological differences between foci that may affect survival and treatment choice. We aimed to evaluate the effect of focal heterogeneity seen in multicentric/multifocal breast tumors on survival. METHODS: We retrospectively collected and analyzed the clinicopathological data of 89 female patients with multifocal/multicentric breast cancer, whose surgical and medical treatment was completed and who were followed up for 5 years. RESULTS: Of all patients, 29.2% (26/89) were heterogeneous. Heterogeneity of these foci was as follows: histologic heterogeneity of index foci (mix type): 15.7% (14/89), histologic heterogeneity of inter-foci: 7.9% (7/89), and immunohistochemical heterogeneity of inter-foci: 10.1% (9/89). When additional foci were evaluated, oncological therapy was changed for 3 (3.3%) of 89 patients. Heterogeneity does not have a significant (p>0.05) effect on recurrence and survival in multicentric/multifocal breast cancers. Pathological N stage is an independent risk factor for disease-free survival (hazard ratio=2.29, 95% confidence interval=1.39-3.76, p=0.001). CONCLUSIONS: In multifocal/multicentric breast cancers, less than 4% of patients may experience heterogeneity requiring change in the therapeutic decision. However, heterogeneity does not have a significant effect on recurrence and survival in multifocal/multicentric breast cancers. The pathological N stage is an independent risk factor for disease-free survival.Keywords
This publication has 15 references indexed in Scilit:
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- Review on Practical Approach in Multiple Breast Carcinomas: Does Each Focus Matter?Chirurgia, 2017
- Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancerBreast Cancer Research and Treatment, 2016
- Original paper Multifocal/multicentric breast carcinomas showing intertumoural heterogeneity: a comparison of histological tumour type and Nottingham histological grade of primary tumour and lymph node metastasisPolish Journal of Pathology, 2015
- Molecular phenotype of the foci in multifocal invasive breast carcinomas: Intertumoral heterogeneity is related to shorter survival and may influence the choice of therapyCancer, 2013
- The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breastHuman Pathology, 2012
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancerActa Oncologica, 2007
- Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve PrognosisJNCI: Journal of the National Cancer Institute, 2006
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004